Article Text

Download PDFPDF
Case report
Cyclophosphamide, bortezomib and dexamethasone (CyBorD): a promising regimen for renal light chain deposit disease
  1. Arunima Dutta1,
  2. Kavitha Kesari1 and
  3. Trevor Singh2
  1. 1Internal Medicine, McLaren Regional Medical Center, Flint, Michigan, USA
  2. 2Karmanos Cancer Institute, McLaren Regional Medical Center, Flint, Michigan, USA
  1. Correspondence to Dr Arunima Dutta; arunima.dutta{at}


Renal light chain deposit disease is a rare disease with rapid progression to renal failure when left untreated. There is no standard treatment available. We present a unique case of renal IgA kappa deposit disease who developed severe decline in renal function within a few months of diagnosis. She was started on a single regimen of cyclophosphamide, bortezomib and dexamethasone (CyBorD) followed by maintenance treatment with bortezomib and dexamethasone leading to rapid improvement of renal function. This is the first case to be reported on renal IgA kappa deposit disease who have responded dramatically to CyBorD without the need for any modification of the regimen or stem cell transplant.

  • haematology (drugs and medicines)
  • renal system
  • medical management
  • chemotherapy
  • therapeutic indications

Statistics from


  • Twitter @Arunima_dutta

  • Contributors AD and TS conceived the idea of writing the case report. AD and KK did the literature search. All authors discussed the literature findings and contributed to the final manuscript. AD wrote the manuscript with support from KK and TS. KK supervised the project. TS provided expert opinion while drafting the manuscript. All authors reviewed, discussed and provided critical feedback to the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.